Cargando…

Using dynamic oral dosing of rifapentine and rifabutin to simulate exposure profiles of long-acting formulations in a mouse model of tuberculosis preventive therapy

Mostrar otras versiones (1)

Administration of tuberculosis preventive therapy (TPT) to individuals with latent tuberculosis infection is an important facet of global tuberculosis control. The use of long-acting injectable (LAI) drug formulations may simplify and shorten regimens for this indication. Rifapentine and rifabutin h...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chang, Yong S., Li, Si-Yang, Pertinez, Henry, Betoudji, Fabrice, Lee, Jin, Rannard, Steven P., Owen, Andrew, Nuermberger, Eric L., Ammerman, Nicole C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cold Spring Harbor Laboratory 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10120629/ https://www.ncbi.nlm.nih.gov/pubmed/37090528 http://dx.doi.org/10.1101/2023.04.12.536604

Ejemplares similares

Using Dynamic Oral Dosing of Rifapentine and Rifabutin to Simulate Exposure Profiles of Long-Acting Formulations in a Mouse Model of Tuberculosis Preventive Therapy
por: Chang, Yong S., et al.
Publicado: (2023)

Assessment of vocation of rifabutin and rifapentine in replace of rifampcin in drug resistance leprosy patients: a molecular simulation study
por: Mohanty, Partha Sarathi, et al.
Publicado: (2017)

A long-acting formulation of rifabutin is effective for prevention and treatment of Mycobacterium tuberculosis
por: Kim, Manse, et al.
Publicado: (2022)

In Vitro Activity of Rifampin, Rifabutin, and Rifapentine against Enterococci and Streptococci from Periprosthetic Joint Infection
por: Albano, Mariana, et al.
Publicado: (2021)

Daily Dosing of Rifapentine Cures Tuberculosis in Three Months or Less in the Murine Model
por: Rosenthal, Ian M, et al.
Publicado: (2007)

Simplifying Rifapentine Dosing for Tuberculosis Treatment and Prevention
por: Podany, Anthony T.
Publicado: (2020)

Activity of a Long-Acting Injectable Bedaquiline Formulation in a Paucibacillary Mouse Model of Latent Tuberculosis Infection
por: Kaushik, Amit, et al.
Publicado: (2019)

1586. In Vitro Activity of Rifampin, Rifabutin, Rifapentine, and Rifaximin Against Biofilms Formed by Staphylococci Isolated from Prosthetic Joint Infection
por: Albano, Mariana, et al.
Publicado: (2019)

Bactericidal Activity Does Not Predict Sterilizing Activity: The Case of Rifapentine in the Murine Model of Mycobacterium ulcerans Disease
por: Almeida, Deepak V., et al.
Publicado: (2013)

Next-Generation Diarylquinolines Improve Sterilizing Activity of Regimens with Pretomanid and the Novel Oxazolidinone TBI-223 in a Mouse Tuberculosis Model
por: Li, Si-Yang, et al.
Publicado: (2023)

Preclinical Evaluation of Long-Acting Emtricitabine Semi-Solid Prodrug Nanoparticle Formulations
por: Curley, Paul, et al.
Publicado: (2023)

Activities of Rifampin, Rifapentine and Clarithromycin Alone and in Combination against Mycobacterium ulcerans Disease in Mice
por: Almeida, Deepak, et al.
Publicado: (2011)

Tuberculosis-HIV treatment with rifampicin or rifabutin: are the outcomes different?
por: Schmaltz, Carolina Arana Stanis, et al.
Publicado: (2019)

Defining the optimal dose of rifapentine for pulmonary tuberculosis: Exposure–response relations from two phase II clinical trials
por: Savic, RM, et al.
Publicado: (2017)

Effect of Rifabutin in Dolutegravir Dosing: A Case Series
por: Mendoza, Maria A., et al.
Publicado: (2022)

The Rationale for Using Rifabutin in the Treatment of MDR and XDR Tuberculosis Outbreaks
por: Sirgel, Frederick A., et al.
Publicado: (2013)

Development and in vitro characterization of drug delivery system of rifapentine for osteoarticular tuberculosis
por: Wu, Jun, et al.
Publicado: (2015)

Retraction: Isoniazid and Rifapentine Treatment Eradicates Persistent Mycobacterium tuberculosis in Macaques
Publicado: (2021)

Pharmacokinetics and safety of rifabutin in young HIV-infected children receiving rifabutin and lopinavir/ritonavir
por: Moultrie, Harry, et al.
Publicado: (2015)

Correction: The Rationale for Using Rifabutin in the Treatment of MDR and XDR Tuberculosis Outbreaks
por: Sirgel, Frederick A., et al.
Publicado: (2015)

Global access of rifabutin for the treatment of tuberculosis – why should we prioritize this?
por: Rockwood, Neesha, et al.
Publicado: (2019)

Impact of Age on Outcome of Rifapentine-Based Weekly Therapy for Latent Tuberculosis Infection
por: Huang, Hung-Ling, et al.
Publicado: (2020)

Cost effectiveness of three months of rifapentine and isoniazid for latent tuberculosis in Syrian refugees
por: Ilaiwy, Ghassan, et al.
Publicado: (2021)

Rifapentine access in Europe: growing concerns over key tuberculosis treatment component
por: Guglielmetti, Lorenzo, et al.
Publicado: (2022)

Cost‐effectiveness of one month of daily isoniazid and rifapentine versus three months of weekly isoniazid and rifapentine for prevention of tuberculosis among people receiving antiretroviral therapy in Uganda
por: Ferguson, Olivia, et al.
Publicado: (2020)

Cost of Delivering 12-Dose Isoniazid and Rifapentine Versus 6 Months of Isoniazid for Tuberculosis Infection in a High-Burden Setting
por: Yuen, Courtney M, et al.
Publicado: (2020)

Pharmacokinetics and Safety of 3 Months of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention in Pregnant Women
por: Mathad, Jyoti S, et al.
Publicado: (2021)

Isoniazid and rifapentine treatment effectively reduces persistent M. tuberculosis infection in macaque lungs
por: Sharan, Riti, et al.
Publicado: (2022)

Xpert MTB/RIF Assay Shows Faster Clearance of Mycobacterium tuberculosis DNA with Higher Levels of Rifapentine Exposure
por: Jayakumar, A., et al.
Publicado: (2016)

Comparison of Compartmental and Non-Compartmental Analysis to Detect Biopharmaceutical Similarity of Intravenous Nanomaterial-Based Rifabutin Formulations
por: Osipova, Nadezhda, et al.
Publicado: (2023)

Rifapentine-Proliposomes for Inhalation: In Vitro and In Vivo Toxicity
por: Patil-Gadhe, Arpana A., et al.
Publicado: (2014)

Randomized pharmacokinetic evaluation of different rifabutin doses in African HIV- infected tuberculosis patients on lopinavir/ritonavir-based antiretroviral therapy
por: Naiker, Suhashni, et al.
Publicado: (2014)

Treatment of latent Mycobacterium tuberculosis infection with 12 once weekly directly-observed doses of isoniazid and rifapentine among persons experiencing homelessness
por: Nwana, Nwabunie, et al.
Publicado: (2019)

Rifabutin Resistance Associated with Double Mutations in rpoB Gene in Mycobacterium tuberculosis Isolates
por: Jing, Wei, et al.
Publicado: (2017)

rpoB Mutations are Associated with Variable Levels of Rifampin and Rifabutin Resistance in Mycobacterium tuberculosis
por: Li, Ma-Chao, et al.
Publicado: (2022)

Potential Economic Viability of Two Proposed Rifapentine-Based Regimens for Treatment of Latent Tuberculosis Infection
por: Holland, David P., et al.
Publicado: (2011)

Safety & Benefits of Directly Observed Therapy with Rifapentine and Isoniazid for Latent Tuberculosis Infection – Less is More?
por: Ha, Lawrence, et al.
Publicado: (2017)

Rifapentine and isoniazid for prevention of tuberculosis in people with diabetes (PROTID): protocol for a randomised controlled trial
por: Ntinginya, Nyanda Elias, et al.
Publicado: (2022)

Pharmacokinetic study of two different rifabutin doses co-administered with lopinavir/ritonavir in African HIV and tuberculosis co-infected adult patients
por: Kouanda, Seni, et al.
Publicado: (2020)

Rifabutin Is Active against Mycobacterium abscessus Complex
por: Aziz, Dinah Binte, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_rc9r637lesp9l20s81mcprg0cb